Burning Rock Biotech (BNR) Income from Continuing Operations: 2020-2025
Historic Income from Continuing Operations for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to -$2.3 million.
- Burning Rock Biotech's Income from Continuing Operations rose 62.43% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 78.00%. This contributed to the annual value of -$45.9 million for FY2024, which is 49.80% up from last year.
- Per Burning Rock Biotech's latest filing, its Income from Continuing Operations stood at -$2.3 million for Q3 2025, which was down 76.56% from -$1.3 million recorded in Q2 2025.
- Burning Rock Biotech's 5-year Income from Continuing Operations high stood at -$1.3 million for Q2 2025, and its period low was -$41.2 million during Q1 2022.
- Its 3-year average for Income from Continuing Operations is -$13.0 million, with a median of -$14.7 million in 2024.
- As far as peak fluctuations go, Burning Rock Biotech's Income from Continuing Operations plummeted by 59.78% in 2021, and later soared by 91.09% in 2025.
- Burning Rock Biotech's Income from Continuing Operations (MRQ) stood at -$40.7 million in 2021, then grew by 16.17% to -$34.1 million in 2022, then grew by 28.51% to -$24.4 million in 2023, then soared by 66.27% to -$8.2 million in 2024, then skyrocketed by 71.89% to -$2.3 million in 2025.
- Its Income from Continuing Operations stands at -$2.3 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$1.8 million for Q1 2025.